UVA Islet Cell Transplantation in Patients With Type I Diabetes
Status unconfirmed · Phase 1
Conditions studied: Diabetes Mellitus, Type 1
In brief
This protocol will provide islet cell transplantation to two separate populations in need of a pancreas transplant: Group I: Islet Cell Transplantation in Type I Diabetics without Kidney Problems Group II: Islet Cell Transplantation in Type I Diabetics Who Have a Stable Functioning Kidney Transplant The targeted patients have very brittle diabetes or dangerous hypoglycemic unawareness and may benefit from transplantation over continuing insulin therapy, even though chronic immunosuppression is required. We believe that in these patients, the islet transplant procedure promises enough potential benefit to justify subjecting patients who have not previously had a transplant to the risk of immunosuppression. In patients who are already subject to the dangers of chronic immunosuppression for other reasons, i.e. to prevent rejection of a kidney allograft, the islet transplantation procedure itself is the principal additional risk and this risk should be minimal. In these patients (our Group II), the potential benefit from improved glycemic control is that it promises to slow or even reverse diabetic complications, such as vascular problems leading to kidney damage. It is this rationale that has made pancreas transplantation a widely accepted option in patients with renal failure, despite the risks associated with whole pancreas transplantation. Islet cell transplantation aims to provide a potentially lower risk procedure that has similar relief from diabetic complications.
Key facts
- Study ID
- NCT00605592
- Run by
- University of Virginia
- People needed
- 20
- Starts
- 2007-01-01
- Expected to finish
- 2012-01-01
- Last updated by the study team
- 2009-02-18
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Type I Diabetes Mellitus for at least 5 years
- Unstable control of diabetes despite intensive care by an endocrinologist, including episodes of dangerously low blood sugars
- Group I must have healthy kidneys
- Group II (islet after kidney) must have a stable kidney allograft for at least 6 months
You may not qualify if…
- Unstable diabetic eye disease
- Poor kidney function
- Type II Diabetes as determined by blood tests
- Any history of cancer, except certain skin cancers
- Pregnant or unwilling to use adequate birth control
- Very high hemoglobin A1c levels
- Poor control of blood pressure, despite use of medications
- Very high insulin requirements
- History of exposure to HIV
- Active Hepatitis B or Hepatitis C infection
Where it is running
- University of Virginia — Charlottesville, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.